Dublin, Oct. 12, 2017 -- The "Gene Therapy - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to Research and Markets' offering
Gene therapy technologies are described in detail including viral vectors, nonviral vectors and cell therapy with genetically modified vectors. Gene therapy is an excellent method of drug delivery and various routes of administration as well as targeted gene therapy are described. There is an introduction to technologies for gene suppression as well as molecular diagnostics to detect and monitor gene expression.
Clinical applications of gene therapy are extensive and cover most systems and their disorders. Full chapters are devoted to genetic syndromes, cancer, cardiovascular diseases, neurological disorders and viral infections with emphasis on AIDS. Applications of gene therapy in veterinary medicine, particularly for treating cats and dogs, are included.
Research and development is in progress in both the academic and the industrial sectors. The National Institutes of Health (NIH) of the US is playing an important part. As of 2016, over 2050 clinical trials were completed, were ongoing or had been approved worldwide.A breakdown of these trials is shown according to the geographical areas and applications.
The markets for gene therapy are difficult to estimate as there is only one approved gene therapy product and it is marketed in China since 2004. Gene therapy markets are estimated for the years 2016-2026. The estimates are based on epidemiology of diseases to be treated with gene therapy, the portion of those who will be eligible for these treatments, competing technologies and the technical developments anticipated in the next decades. In spite of some setbacks, the future for gene therapy is bright.The markets for DNA vaccines are calculated separately as only genetically modified vaccines and those using viral vectors are included in the gene therapy markets
The voluminous literature on gene therapy was reviewed and selected 750 references are appended in the bibliography.The references are constantly updated. The text is supplemented with 76 tables and 22 figures.
Profiles of 189 companies involved in developing gene therapy are presented along with 240 collaborations. There were only 44 companies involved in this area in 1995. In spite of some failures and mergers, the number of companies has increased more than 4-fold within a decade.
Key Topics Covered:
Part I: Technologies & Markets
Executive Summary
1. Introduction
2. Gene Therapy Technologies
3. Clinical Applications of Gene Therapy
4. Gene Therapy of Genetic Disorders
5. Gene Therapy of Cancer
6. Gene Therapy of Neurological Disorders
7. Gene Therapy of Cardiovascular Disorders
8. Gene therapy of viral infections
9. Research, Development and Future of Gene Therapy
10. Regulatory, Safety, Ethical Patent Issues of Gene Therapy
11. Markets for Gene Therapy
12. References
Part II: Companies
13. Companies involved in Gene Therapy
For more information about this report visit https://www.researchandmarkets.com/research/fww8l7/gene_therapy
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Genomics


Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power
Disney Agrees to $10 Million Settlement Over Child Privacy Violations on YouTube
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 



